Medtronic, Inc. (Minneapolis, MN) announced that a new analysis of clinical data on the company’s Endurant abdominal aortic aneurysm (AAA) stent graft system demonstrated consistent performance in treating AAAs across a range of patient anatomies, from relatively straightforward to highly complex. Prof. Hence Verhagen, MD, presented the data at the 35th Charing Cross International Symposium in London, United Kingdom. Prof. Verhagen is Chief of Vascular Surgery at the Erasmus Medical Center in Rotterdam, the Netherlands.
Medtronic, Inc. (Minneapolis, MN) announced that the Sentrant introducer sheath has received CE Mark approval and will soon be launched internationally.
Aptus Endosystems announced on 2 April 2013 that it received CE clearance for its thoracic-length Heli-FX System. Similar to the original Heli-FX system that was cleared for European distribution in May 2011 and designed for treating abdominal aortic aneurysms, the new system consists of a longer delivery device with additional tip configurations to bring the innovative helical EndoAnchor technology to the treatment of thoracic aortic aneurysms.
The first European patients with peripheral arterial disease have been treated with a new ultra low-profile micro-balloon catheter from Cook Medical that allows physicians to treat arterial lesions in the leg below the knee, according to the company.
F Care Systems USA, LLC (North Miami, FL) announced the launch of its EVRF device to provide endovenous radiofrequency treatment of varicose veins. The EVRF machine has received 510(k) clearance from the US Food and Drug Administration (FDA). F Care, headquartered in Aartselaar, Belgium, previously released the EVRF in the United Kingdom and other countries as Veinwave. With F Care s branch in the United States, the company will be offering full upgrades, training, and support to all current Veinwave and EVRF customers.
Paclitaxel-eluting balloons are associated with favourable functional and clinical outcomes at two years in patients with femoropopliteal arterial disease requiring percutaneous revascularisation, according to a study published in the Journal of the American College of Cardiology: Cardiovascular Interventions in March 2013.
Two-year data from an independent, prospective, multicenter registry aimed at assessing outcomes of femoropopliteal angioplasty with a paclitaxel-eluting balloon (PEB) (In.Pact Admiral, Medtronic, Inc., Minneapolis, MN) were recently published by Antonio Micari, MD, et al in the Journal of the American College of Cardiology: Cardiovascular Interventions
In a small cohort, Thomas Zeller, Universitäts-Herzzentrum, Bad Krozingen, Germany, and colleagues, investigated the use of the Proteus embolic capture angioplasty balloon for peripheral vascular disease. They reported on their initial experience using the angioplasty balloon in a study published in the Journal of Endovascular Therapy.
The Society for Cardiovascular Angiography and Interventions (SCAI) has released a statement in response to a study showing that minimally invasive procedures significantly lower health payer costs and result in fewer missed workdays when compared to open surgery. The study by Andrew J. Epstein, PhD, et al was published online ahead of print in Journal of the American Medical Association (JAMA) Surgery.
El tratamiento con células de médula ósea autólogas podría reducir las amputaciones en los pacientes con isquemia de miembros inferiores crítica (IMIC).
Gore has announced the US and European launch of lower profile contralateral leg components for the Gore Excluder AAA Endoprosthesis used to treat abdominal aortic aneurysms.
New research provides early evidence that “good” cholesterol may possess anti-aneurysm forming properties. In laboratory-based investigations, scientists found that increased levels of high-density lipoproteins (HDL) blocked the development of aortic aneurysms.
On 4 March 2013, Tenaxis Medical, a medical device company focused on the development of functionally designed surgical sealants, has received FDA approval to bring its innovative ArterX Surgical Sealant to the market. The company plans to start commercialisation of ArterX in the United States early in 2013.
Boston Scientific announced, on the 6 March 2013 the launch of its 0.035 and 0.018 Rubicon Support Catheter in the USA. The device is designed to assist physicians with placement and support of guidewires that are used in peripheral vascular procedures to deliver stents and balloons to open blockages in the legs and other peripheral arteries. Boston Scientific is also launching the 0.035 Rubicon Support Catheter in Europe after the launch of the 0.018 size that was introduced in that region last autumn.
Bolton Medical on 1 March, 2013 announced the Treovance Abdominal Stent-Graft with Navitel Delivery System received CE mark and its international launch. This device will provide physicians with a device indicated for the endovascular treatment of abdominal aortic aneurysms in patients with a proximal neck length of up to 10mm or an infrarenal neck angle up to 75 degrees, according to the company.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos